Cell-free Methylation Markers
Conditions
Brief summary
The subjects of this study were patients with liver cancer diagnosed by physicians according to AASLD clinical criteria or pathological biopsy. Those who plan to receive systemic drug treatment for liver cancer in National Taiwan University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq, Strivarga, Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yervoy. Weak and uncooperative patients were excluded from blood tests, which were performed with full informed consent for relevant tumor markers (AFP ,PIVKA-II and methylation analysis). The data are then counted and compared.
Interventions
None listed
Sponsors
National Taiwan University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with liver cancer by AASLD clinical criteria or pathological slides Patients planning to receive systemic drug therapy for liver cancer at National Taiwan University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq, Strivarga, Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yevoy. 2. Over 20 years old. 3. In the case of informed consent, willing to sign the consent form of the subjects.
Exclusion criteria
1. Patients who are weak and unable to cooperate with blood test. 2. Kidney dysfunction, serum creatinine greater than 1.5 x UNL (normal value) and no hemodialysis treatment, who are judged to be unwell for computed tomography or MRI contrast agent injection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate efficacy | 3 month after treatment | Correlation of methylation profiling results and tumor treatment response. |
Countries
Taiwan
Contacts
Primary ContactKai-Wen Huang
Outcome results
None listed